GH Research PLC Ordinary Shares
Symbol: GHRS (NASDAQ)
14.55
▲ (1.75%) 0.250
Company Description:
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Key Stats
- Today's Open: $14.417
- Today's High: $14.55
- Today's Low: $14.417
- Today's Volume: 0
- Yesterday Close: $14.3
- Yesterday High: $14.6
- Yesterday Low: $13.94
- Yesterday Volume: 304.11K
- Last Min Volume: 0
- Last Min High: $14.55
- Last Min Low: $14.417
- Last Min VWAP: $0
Company Profile
- Name: GH Research PLC Ordinary Shares
- Website: https://www.ghres.com
- Listed Date: 2021-06-25
- Location: ,
- Market Status: Active
- CIK Number: 0001855129
- SIC Code:
- SIC description:
- Market Cap: $887.02M
- Round Lot: 100
- Outstanding Shares: 62.03M
- Asset Type: CS
RECENT FILINGS FOR GHRS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-12 | 6-K | View |
| 2025-09-09 | 6-K | View |
| 2025-08-29 | 6-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-07 | 6-K | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
| 2025-08-01 | 6-K | View |
| 2025-07-29 | 20-F/A | View |
| 2025-07-23 | 6-K | View |
| 2025-06-20 | 6-K | View |
| 2025-06-18 | 6-K | View |
| 2025-06-13 | 6-K | View |
| 2025-05-27 | 6-K | View |
| 2025-05-21 | 6-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | 6-K | View |
| 2025-05-12 | SCHEDULE 13G | View |
Latest News on GHRS